ERBB2 and breast carcinoma: In contrast to Qin et al. [143], a study by Sumoza-Toledo et al. [177] demonstrated that high expression was associated with improved survival outcomes in both the human epidermal growth factor receptor 2 (HER2)+ and ER, breast cancer subtypes.